GYN

Hologic, Inc. (NASDAQ: HOLX) reported fiscal second-quarter results that prompted Leerink to drop its bullish stance on the women's health-focused medical technology company.  The Analyst Leerink's Richard Newitter downgraded Hologic's stock rating from Outperform to Market...